What to expect in 2018, the cancer death rate has dropped again and is CRISPR the Jack of All Trades?
(GEN, 1/1/2018, William Iannuccilli)
After years of development, the gene editing tool known as CRISPR/Cas9 is finally beginning to realize its full potential in the genome-editing arena. The hope for CRISPR is that one day it will be used to cure some of the most devastating inherited disorders and cancers. Looking ahead into 2018, CRISPR continues to be a hot topic and gene-editing methods are advancing at a rapid pace. They are being applied in a wide range of applications, including medical/pharmaceutical, agricultural, and animal health.
(Nature, 1/12/2018, Elizabeth Gibney)
According to Nature, moon missions, ancient genomes and a publishing showdown are set to shape research in 2018. In case you missed it, we also posted our Hot Topics for 2018. What are you keeping an eye on in 2018?
(Washington Post, 1/4/2018, Laurie McGinley)
According to a new report by the American Cancer Society, the nation’s overall cancer death rate declined 1.7 percent in 2015, the latest indication of steady, long-term progress against the disease. But the report, released this week, shows that Americans’ No. 2 killer remains a formidable, sometimes implacable, foe. An estimated 609,000 people are expected to die of the ailment this year, while 1.74 million will be diagnosed with it. Overall, the cancer death rate has dropped from 215.1 per 100,000 population in 1991 to 158.6 per 100,000 in 2015, due largely to declines in smoking and advances in early detection, prevention and treatment. U.S. rates of cancer incidence over the past decade were stable for women and decreased by about 2 percent annually for men. Still, the lifetime probability of being diagnosed with the disease is slightly higher for men than for women, with adult height accounting for about a third of the difference. Studies have shown that taller people have a greater risk of cancer.
—Compiled by Social Media Specialist Jillian Scola